Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

NCT06230185 is registered in ClinicalTrials.gov with Personalis Inc. as lead sponsor.

NCT NCT06230185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06230185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Lead sponsor
Personalis Inc.
Phase
Observational
Overall status
Recruiting
Start date
November 9, 2023
Completion date
December 31, 2025
Enrollment
422 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease, tnbc - triple-negative breast cancer